• Edna M. McKim RN, BScN, MN

    Corresponding authorSearch for more papers by this author
    • Edna M. McKim, RN, MN, is a clinical nurse specialist. She has had experience as a staff nurse and teacher in the perinatal area and has been the coordinator of the Newfoundland and Labrador Perinatal Program, St. John's, Newfoundland, Canada. She is currently an assistant professor, School of Nursing, Memorial University of Newfoundland. She is a member of Sigma Theta Tau and NAACOG.

School of Nursing, Memorial University of Newfoundland. St. John's. Newfoundland, Canada A1B 3V6.


In animal studies, fetal loss, decreased fetal weight and size, and major skeletal defects have been reported when dosages of more than 80 mg/kg of caffeine were used. Human epidemiologic studies that examine the relationship between caffeine use and congenital abnormalities are not conclusive; however, there is some evidence to suggest a caffeine effect upon fetal growth patterns. Because caffeine drinking is so often associated with the use of other drugs such as tobacco, it is difficult to ascertain which drug has the effect on growth, or if it is a combined effect from both drugs. A tripling of the half-life of caffeine in the last two trimesters of pregnancy resulting in much higher caffeine blood levels for both mother and fetus, combined with the neonate's inability to metabolize caffeine, could account for the indications of neonatal caffeine withdrawal observed in the first week after birth.